Viatris (VTRS) is a pharmaceutical company that sells a variety of different drugs. The company plans to offer its first ever dividend and is currently trading at a very low valuation. Does that make it a Buy? Read more to find out.Viatris (VTRS) is a Pittsburgh-based healthcare business that provides medicines. Previously conducting business under the name of Mylan (NASDAQ:VTRS) NV, VTRS makes generic drugs. Mylan ended up merging with a division of Pfizer (NYSE:PFE) known as Upjohn, resulting in the name change.
VTRS was trading around $13 for much of April and early May. The stock then climbed to $15 in the second week of May and even broke through $16 this past week. However, if you take a look at VTRS's six-month chart, you would find the stock traded between $16 and $18 between the end of 2020 and the first couple of months of 2021. VTRS tumbled in late February, dropping from $18 to $13.
Is VTRS a Buy now? Let's find out.